Nippon Shinyaku To Submit NDA For Azacitidine
This article was originally published in PharmAsia News
Executive Summary
Osaka-based Japanese drug maker Nippon Shinyaku plans to submit an NDA for NS-17 (azacitidine) for myelodysplastic syndrome within the year, disclosed company president Shigenori Maekawa during a Nov. 10 earnings call